Skip to main content

CardioDx Raises $35M

NEW YORK (GenomeWeb) – CardioDx today announced the close of a $35 million financing round.

The funds will be used to expand the commercial use of Corus CAD and to support the company's development of other genomic tests for coronary artery disease, CardioDx said. Corus CAD is a gene expression-based test for assessing non-diabetic patients who display symptoms suggestive of obstructive CAD. 

Along with CardioDx's existing investors, Alberta Investment Management participated in the round.  

In July the Redwood City, Calif.-based company said in a regulatory document that it raised $21 million toward a targeted goal of $25 million. The $35 million figure includes the July financing. 

CardioDx filed for an initial public offering in October 2013 but has not gone public yet.

 

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.